Abstract: Use of a flurbiprofen axetil (FPA) in preparing a pharmaceutical composition for fever relief in a patient through an intravenous administration route is provided, where the pharmaceutical composition includes FPA at a content of 10 mg to 40 mg, preferably 10 mg to 35 mg, 15 mg to 35 mg, and 15 mg to 30 mg, 15 mg, and 30 mg. The pharmaceutical composition can be safely and effectively used for fever relief in an adult patient. Surprisingly, the pharmaceutical composition has a comparable antipyretic effect and duration to a pharmaceutical composition with high-content FPA, but the pharmaceutical composition with low-content FPA has less adverse reactions. Compared with ibuprofen injections, a single administration of the low-dosage FPA provided by the present disclosure can maintain an antipyretic effect for 6 hours to 10 hours or more, which significantly reduces the administration frequency and improves the compliance of a patient.